[1] Fanning G C, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure[J]. Nat Rev Drug Discov, 2019, 18(11): 827-844. [2] Hou J, Zhang W, Xie Q, et al. Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B[J]. N Engl J Med, 2024, 391(22): 2098-2109. [3] Yuen M F, Lim S G, Plesniak R, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection[J]. N Engl J Med, 2022, 387(21): 1957-1968. [4] Meng F, Zhao J, Tan A T, et al. Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial[J]. Hepatol Int, 2021, 15(6): 1402-1412. [5] Schreiber S, Honz M, Mamozai W, et al. Characterization of a library of 20 HBV-specific MHC class II-restricted T cell receptors[J]. Mol Ther Methods Clin Dev, 2021, 23: 476-489. [6] Tan A T, Schreiber S. Adoptive T-cell therapy for HBV-associated HCC and HBV infection[J]. Antiviral Res, 2020, 176: 104748. [7] Heim K, Sagar, Sogukpinar O, et al. Attenuated effector T cells are linked to control of chronic HBV infection[J]. Nat Immunol, 2024, 25(9): 1650-1662. [8] Cheng Y, Gunasegaran B, Singh H D, et al. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma[J]. Immunity, 2021, 54(8): 1825-1840. [9] Hoogeveen R C, Robidoux M P, Schwarz T, et al. Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection[J]. Gut, 2019, 68(5): 893-904. [10] Wu Y, Ding Y, Shen C. A Systematic Review of T Cell Epitopes Defined from the Proteome of Hepatitis B Virus[J]. Vaccines (Basel), 2022, 10(2). [11] Ou G, Xu H, Yu H, et al. The roles of HLA-DQB1 gene polymorphisms in hepatitis B virus infection[J]. J Transl Med, 2018, 16(1): 362. [12] Nishida N, Sawai H, Kashiwase K, et al. New susceptibility and resistance HLA-DP alleles to HBV-related diseases identified by a trans-ethnic association study in Asia[J]. PLoS One, 2014, 9(2): e86449. [13] Huang Y H, Liao S F, Khor S S, et al. Large-scale genome-wide association study identifies HLA class II variants associated with chronic HBV infection: a study from Taiwan Biobank[J]. Aliment Pharmacol Ther, 2020, 52(4): 682-691. [14] Wang W C, Lin Y S, Chang Y F, et al. Association of HLA-DPA1, HLA-DPB1, and HLA-DQB1 alleles with the long-term and booster immune responses of young adults vaccinated against the hepatitis B virus as neonates[J]. Front Immunol, 2021, 12: 710414. |